Drug

Alrizomadlin clinical trials

Also written APG-115.

studies test it: 9
open now: 5
in phase 3: 0
first study started: 2016

How each study uses alrizomadlin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the alrizomadlin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

alrizomadlin: 2

Development codes

APG-115: 7

Studies by the year they started

9 studies that test it; most in 2021 (2)

Studies that test alrizomadlin, by start year
Year	Studies
2016	1
2018	1
2019	1
2020	1
2021	2
2023	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 7
Phase 2: 8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Salivary Gland Neoplasms: 1
Uveal Melanoma: 1
Lymphoma: 1
Neuroblastoma: 1
Neurofibrosarcoma: 1
Leukemia, Prolymphocytic, T-Cell: 1
Liposarcoma: 1
Leukemia, Myeloid, Acute: 1
Mesothelioma, Malignant: 1

Who runs them

Industry 6 · Other 3

Ascentage Pharma Group Inc. (6) · University of Michigan Rogel Cancer Center (1) · AeRang Kim (1) · National Cancer Institute (NCI) (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test alrizomadlin.

Jun 2027APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsPhase 1/2 · Ascentage Pharma Group Inc.
Oct 2027Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTPhase 1/2 · AeRang Kim

Studies

Open first, then newest update. How each study uses alrizomadlin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Given beside what is tested · 1 — alrizomadlin is usual care or a partner of the new treatment

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingPhase 1Ascentage Pharma Group Inc.NCT04275518Written as APG-115

Codes

What other systems call alrizomadlin · ClinicalTrials.gg INT014284

UNII (FDA) 15QAU0SI9JALRIZOMADLINConfirmed FDA, Wikidata
Wikidata Q76808325alrizomadlinConfirmed FDA, Wikidata
NCI Thesaurus C132991AlrizomadlinOne source FDA
DrugBank DB17549One source Wikidata

System	Code	Name there	Checked by
UNII (FDA)	15QAU0SI9J	ALRIZOMADLIN	Confirmed FDA, Wikidata
Wikidata	Q76808325	alrizomadlin	Confirmed FDA, Wikidata
NCI Thesaurus	C132991	Alrizomadlin	One source FDA
DrugBank	DB17549	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.